NCT02392637 - Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 2, 2015

Primary Completion Date

August 13, 2020

Study Completion Date

August 13, 2020

Conditions

Stage III Intrahepatic Cholangiocarcinoma AJCC v7Stage IIIA Gallbladder Cancer AJCC v7Stage IIIB Gallbladder Cancer AJCC v7Stage IVA Gallbladder Cancer AJCC v7Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7Stage IVB Gallbladder Cancer AJCC v7Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7Unresectable Extrahepatic Bile Duct CarcinomaUnresectable Gallbladder Carcinoma

Interventions

DRUG

Cisplatin

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nab-paclitaxel

Given IV

Trial Locations (3)

55905

Mayo Clinic, Rochester

77030

M D Anderson Cancer Center, Houston

85259

Mayo Clinic in Arizona, Scottsdale

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER